Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization

Transfusion

Volumn 52, Issue 1, 2012, Pages 55-62

  Vishnu, Prakash ^a,b   Roy, Vivek ^a,b   Paulsen, Athena ^a,b   Zubair, Abba C ^a,b  

^a Division of Laboratory Medicine and Pathology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG COST; DRUG USE; FEMALE; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MORNING DOSAGE; NEUTROPHIL COUNT; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 84855346857     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03206.x     Document Type: Article

References (40)

1. Bensinger W, DiPersio JF, McCarty JM,. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-95.
2. Gasova Z, Marinov I, Vodvarkova S, Bohmova M, Bhuyian-Ludvikova Z,. PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients. Transfus Apher Sci 2005; 32: 167-76. (Pubitemid 40387370)
3. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C,. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-77. (Pubitemid 30159857)
4. Jillella AP, Ustun C,. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 2004; 13: 598-606. (Pubitemid 40052636)
5. Sola C, Maroto P, Salazar R, Mesia R, Mendoza L, Brunet J, Lopez-Pousa A, Tabernero JM, Montesinos J, Pericay C, Martinez C, Cancelas JA, Lopez-Lopez JJ,. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4: 195-209. (Pubitemid 30011407)
6. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR, Moreb JS,. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-20. (Pubitemid 36410987)
7. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF,. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-56.
8. Gertz MA, Wolf RC, Micallef IN, Gastineau DA,. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396-403.
9. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W,. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-94. (Pubitemid 24175570)
10. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner CD,. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-55.
11. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD,. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-6. (Pubitemid 28122743)
12. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA,. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-42. (Pubitemid 47299979)
13. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S,. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280-1. (Pubitemid 351833803)
14. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H, Maghfoor I,. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-78. (Pubitemid 351517224)
15. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S,. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-23.
16. Lapidot T, Petit I,. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-81. (Pubitemid 35286613)
17. Nervi B, Link DC, DiPersio JF,. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006; 99: 690-705. (Pubitemid 44521989)
18. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC,. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30. (Pubitemid 37248839)
19. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF,. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-102. (Pubitemid 41095043)
20. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.
21. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
22. Inadomi JM,. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol 2004; 16: 535-42. (Pubitemid 38703861)
23. Zubair AC, Rymer R, Young J, Keeton U, Befort R, Nolot B, Evans C, Bleach T, Torloni A,. Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants. J Clin Apher 2009; 24: 6-11.
24. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, Fung H, Bhatia R, Kashyap A, Molina A, O'Donnell MR, Parker PA, Sniecinski I, Snyder DS, Spielberger R, Stein A, Forman SJ,. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-93. (Pubitemid 30120817)
25. Vantelon JM, Koscielny S, Brault P, Bourhis JH, Ribrag V, Pico J, Fenaux P, Munck JN,. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant 2000; 25: 495-9. (Pubitemid 30137863)
26. Lysak D, Koza V, Jindra P,. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci 2005; 33: 275-83. (Pubitemid 41586193)
27. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ,. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-97.
28. Blanco J, Barretina J, Henson G, Bridger G, De Clercq E, Clotet B, Este JA,. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob Agents Chemother 2000; 44: 51-6. (Pubitemid 30010671)
29. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ,. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294-300. (Pubitemid 36857336)
30. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A,. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6. (Pubitemid 32225831)
31. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA,. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003; 22: 8093-101. (Pubitemid 37487300)
32. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T,. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64: 2817-24. (Pubitemid 38500620)
33. Gazitt Y, Akay C,. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells 2004; 22: 65-73. (Pubitemid 38018782)
34. Corcione A, Arduino N, Ferretti E, Raffaghello L, Roncella S, Rossi D, Fedeli F, Ottonello L, Trentin L, Dallegri F, Semenzato G, Pistoia V,. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res 2004; 10: 964-71. (Pubitemid 38198897)
35. Juarez J, Bendall L,. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 2004; 19: 299-309. (Pubitemid 38111273)
36. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK,. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523-8.
37. Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J,. Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion 2003; 43: 614-21. (Pubitemid 36506358)
38. To LB, Haylock DN, Simmons PJ, Juttner CA,. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58. (Pubitemid 27143269)
39. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T,. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-94. (Pubitemid 34752479)
40. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK,. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-9.